Joint Pain and Inflammation as Metabolic Symptoms in Perimenopause

A woman in her late 40s who feels her knees catch on the stairs or her shoulder pull when she reaches for a top shelf is usually handed the same explanation: this is what aging feels like. The research says something more specific. Joint pain and inflammation during the perimenopausal transition trace back to estrogen's direct role in regulating joint tissue, not to the simple passage of years. A 2025 review in the International Journal of Molecular Sciences lays out three separate pathways through which estrogen affects knee osteoarthritis pain: inflammatory regulation, inhibition of cellular senescence and apoptosis, and modulation of neurotransmitters involved in pain. None of those three is a byproduct of getting older in the way a graying hairline is. Osteoarthritis and other joint conditions do become more common in midlife anyway, so the hormonal signal gets buried under an easier, incomplete story, and clinicians reach for "aging" when the tissue itself is responding to something far more traceable. A 2024 review in Climacteric proposed a name for the fuller picture: the "musculoskeletal syndrome of menopause," a framework that gathers joint pain, tendon problems, cartilage changes, and muscle loss under one hormonal cause rather than treating them as four unrelated complaints. More than 70% of perimenopausal women report musculoskeletal symptoms during the transition, and roughly one in four describe them as disabling enough to interfere with daily life, numbers that make this far too common to file away as coincidence.

What Estrogen Does for Joints, Tendons, and Cartilage

To understand why its loss causes so much trouble, it helps to look at what estrogen is doing while it is still around in steady supply. On the inflammatory side, estrogen inhibits TNF-α, a signaling molecule that, left unchecked, degrades muscle proteins and interferes with tissue repair (TNF-α's role is one of balance: transient signaling from it also supports muscle regeneration, even as sustained signaling causes harm). The 2025 IJMS review identifies this inflammatory brake as one of the primary mechanisms through which estrogen protects joint tissue day to day.

Estrogen also keeps cartilage pliable and supports the production of synovial fluid, the substance that lubricates joints and lets them move without friction. Estrogen-responsive cells regulate how cartilage is broken down and rebuilt, so this isn't a side effect of estrogen's presence elsewhere in the body but a direct function carried out at the joint itself. Collagen synthesis is another front: estrogen stimulates production of collagen, the structural protein that makes up tendons, ligaments, and cartilage. A human study by Hansen and colleagues in 2009 found that estrogen therapy significantly increased peritendinous collagen synthesis rates in postmenopausal women. The same study found that women receiving estrogen showed no difference in tendon cross-sectional area compared with untreated women, but did show lower tendon stiffness, measured by Young's modulus, than those not on therapy. That detail matters because it shows estrogen's effect on tendon mechanics is not a one-directional "more estrogen, stronger tendon" relationship. It changes tendon behavior in specific, measurable ways.

Finally, estrogen modulates how the brain and spinal cord process pain signals. Stable estrogen levels are associated with a higher pain threshold, so the hormone regulates both the physical integrity of the joint tissue itself and the nervous system's sensitivity to signals coming from that tissue, and losing one can make the joint hurt more for the same amount of wear. Lose both and small amounts of mechanical stress can register as significant pain.

How perimenopause disrupts joint tissue through volatility, not just decline

Here is where the conventional "declining hormones" story falls short. Estrogen during perimenopause doesn't fall in a smooth line from high to low. It spikes and crashes unpredictably: a single cycle can produce estrogen levels higher than a woman experienced in her 30s, immediately followed by a cycle in which estrogen is barely detectable. The 2025 IJMS review describes estrogen production during this period as becoming "significantly decreases and becomes more erratic," and specifies that the decline is "not gradual" but occurs sharply, a pattern that the review ties directly to the range of symptoms perimenopausal women report.

Why does this matter clinically? Because it means joints, tendons, and pain-processing pathways are reacting to volatility, not simply to sustained low estrogen, which explains why a woman's labs can come back looking unremarkable while her joints feel considerably worse than they did a year earlier. Sleep disruption and hot flashes, both themselves products of estrogen instability, can compound the effect, making joints feel worse without any new structural damage having occurred.

A near-natural experiment makes the case even more clearly. Women taking aromatase inhibitors, drugs that sharply and rapidly reduce estrogen levels, commonly develop significant joint pain as a documented side effect. That pattern appears on a timeline of weeks, far too fast to be explained by aging, which shows that estrogen withdrawal itself, independent of the passage of time, is the direct driver of joint symptoms.

The STRAW+10 staging system gives this process a map. Stage -2, early in the menopausal transition, involves variable FSH levels along with low AMH and inhibin-B, and cycles that become irregular, defined as a persistent difference of seven days or more in cycle length. Stage -1, late perimenopause, often brings intervals of 60 days or more without menstruation, and this is typically when vasomotor symptoms like hot flashes begin, even though estrogen can still swing considerably at this stage. A 2025 study from Monash University, published in The Lancet Diabetes & Endocrinology and drawing on a large cohort of women aged 40 to 69, found that hallmark perimenopause symptoms can appear before cycle changes become noticeable. Many women are already physiologically in perimenopause, hormonal volatility and all, well before they or their clinicians recognize what is happening.

The range of joints and tissues affected

Once the mechanism is clear, the pattern of symptoms stops looking random. Arthritis Society Canada's 2026 data shows that more than 70% of perimenopausal women experience musculoskeletal symptoms during this transition.

Specific tendon problems cluster in this same window. Frozen shoulder, known clinically as adhesive capsulitis, and gluteal tendinopathy both appear disproportionately in women between 40 and 60, a pattern consistent with the timing of perimenopausal hormonal disruption. An 11-year longitudinal study of midlife women reinforces the point further: women who had never used hormone therapy had nearly three times the odds, an odds ratio of 2.7, of developing radiographically confirmed osteoarthritis in both the knee and hand combined, compared with women who had used it. Structural joint outcomes, in other words, track the hormonal environment and not simply the calendar.

Morning stiffness that eases relatively quickly within an hour or so is typical of menopausal arthralgia, while stiffness that persists much longer, or joints that are warm and visibly swollen, points toward inflammatory arthritis and calls for a different kind of evaluation. That distinction sets up the next question directly. If perimenopausal joint pain can look so much like other conditions, how does a woman, or her clinician, tell them apart?

Conditions that produce similar joint symptoms

Joint pain in a woman in her 40s sits at the center of a genuinely crowded differential, and the clinical error can run in either direction: perimenopause gets missed because another diagnosis seems to explain the symptoms, or another condition gets missed because perimenopause is assumed to explain everything.

Rheumatoid arthritis is one of the clearest examples. RA symptoms often improve temporarily during pregnancy, when estrogen is high, and tend to worsen after menopause, when estrogen's normal protective effect on joints against RA's inflammatory activity fades. That overlap cuts both ways clinically: a woman with existing RA may have perimenopausal joint changes folded into her RA diagnosis without being separately evaluated, while a woman with undiagnosed early RA may be told her symptoms are simply perimenopause. Telling the two apart requires serological testing: rheumatoid factor, anti-CCP antibodies, and inflammatory markers.

Hypothyroidism presents a similarly tangled picture. A TSH test can confirm or rule out thyroid disease, which makes it one of the more straightforward pieces of this puzzle to resolve.

Fibromyalgia belongs in the same conversation. Some women end up with a fibromyalgia diagnosis when hormonal change, not a separate chronic pain condition, is driving what they feel.

None of this means the differential is unmanageable. What's needed is a workup broad enough to account for all the plausible explanations at once. That requires data, which raises the next question: what can hormone testing actually tell a clinician in this situation, and what does it leave out?

What hormone testing can and cannot tell you

Testing has real value here, but its limits need to be stated honestly before its usefulness can be put to proper use. Updated guidelines from the European Society of Endocrinology, issued in October 2025, state that in women over 45, biochemical testing is not required to diagnose or manage perimenopause or menopause. These women may already show elevated FSH during the late reproductive phase, and a normal FSH reading does not rule out perimenopause, a point the guidelines make explicitly.

When testing does make sense, usually for atypical symptoms, for women under 40, or when the clinical picture is ambiguous, FSH is best measured on day 2 through 5 of the menstrual cycle, or after an extended stretch without menstruation. High FSH paired with low estradiol is consistent with menopause, but estradiol fluctuates just as much as FSH during this period, so a single estradiol reading needs to be read in context.

Combining markers improves the picture. A 2025 cross-sectional study found that measuring estradiol together with beta-CTX, a marker of bone resorption, outperforms either measurement taken alone for identifying perimenopausal women at high risk of bone loss. That finding illustrates something broader than bone health alone: a curated combination of markers, read together, carries more information than any single test taken in isolation.

The same logic extends to joint symptoms. Because perimenopause is defined by volatility rather than a fixed low point, a single test on a single day captures only one frame of a process that is constantly moving. Tracking symptoms across cycles, logging which joints ache and on which day of the cycle, builds a record of the volatility pattern that no one-time lab draw can show. That kind of longitudinal data doesn't replace testing, but it gives testing something to be measured against.

Why musculoskeletal symptoms remain underrecognized in perimenopausal care

Given how well-documented these mechanisms are, and how common the symptoms are, musculoskeletal complaints remain strikingly underscreened in perimenopausal care. A 2025 qualitative study of women presenting to physiotherapy found that all but one participant reported ongoing uncertainty, both at the first appointment and throughout treatment, about whether their symptoms were caused by menopausal changes, by aging, or by something more serious. That finding suggests the clinical encounter itself, as currently structured, is not resolving the question for most women who walk in with it.

A 2026 meta-analysis led by Guilherme S. Nunes and colleagues, drawing on a very large cohort of women, confirmed that musculoskeletal symptoms are significantly elevated during perimenopause compared with other stages of life. That finding gives a sense of scale: the population affected is not a small subset of unusually symptomatic women but a substantial share of everyone moving through the transition.

The cost of this gap isn't only physical discomfort. Women who cannot get a coherent explanation for what they're feeling often scale back activity, quietly accept declining function as inevitable, or move from specialist to specialist without landing on an answer. Each of those outcomes represents a woman whose joint pain had a traceable cause that the system didn't name for her.

Advocating for yourself when joint pain and perimenopause intersect in a clinical setting

Women who come to an appointment with longitudinal data and specific, mechanistically grounded questions are in a stronger position to get useful answers, and are less likely to be waved off with a vague reference to aging. One might argue that patients shouldn't have to do this kind of preparation to be taken seriously, and that's a fair criticism of the system described in the previous section. It doesn't change the fact that, in the current clinical environment, preparation changes outcomes.

Connecting the symptom timeline to the hormonal timeline is the first and most concrete step. Tracking which joints ache and when, alongside cycle irregularity, hot flashes, and sleep disruption, turns a vague complaint into a documented pattern that a clinician can actually work with. Naming the differential directly, rather than waiting for a clinician to raise it, is worth doing. Rheumatoid arthritis, hypothyroidism, and fibromyalgia each have specific tests that can confirm or rule them out, so asking for TSH, rheumatoid factor, and anti-CCP antibodies alongside a hormonal evaluation is a precise, answerable request.

It helps just as much to understand what FSH and estradiol results can and cannot say. A single normal FSH reading does not rule out perimenopause, and a single estradiol reading cannot capture the volatility that may be driving the pain. Being able to explain that distinction to a clinician, or to hand over a clear written summary of symptoms tracked across several cycles, shifts the conversation from "is this just aging?" toward a specific, answerable question about hormonal volatility and its effect on joint tissue. Personalized, longitudinal data is the tool that makes self-advocacy, in a system still catching up to the biology, actually possible.